EC Innovations, in collaboration with Jademond Digital, has announced the release of its joint 2026 English-Chinese Simplified Localization Benchmark Report. The comprehensive study examines how large language models (LLMs), machine translation, and human expertise perform across localization processes. Its focus
When an e-commerce brand expands beyond its home market, it faces one of its biggest challenges: how to connect with international customers in a way that feels natural, trustworthy, and authentic. While the internet provides global reach, consumer trust is
The first half of 2025 has confirmed a seismic shift in the pharmaceutical landscape: GLP-1 receptor agonists — a class of new drug therapies for diabetes and obesity — now dominate global sales charts. Among all medicines worldwide, treatments for
The biotech sector is on the cusp of a surge in novel therapies. Recent FDA approvals were driven by first-in-class drugs and expedited review paths. Nearly half of 50 new biologic and molecular therapies approved by 2024 will be first-in-class
Over the past decade, China’s biotech sector has surged onto the world stage in drug licensing. From just 55 China‐related deals in 2015, Chinese biopharma companies were involved in 213 deals by 2024. Total deal value jumped from $3.1 billion
As globalization accelerates, efficient management of localization projects becomes critical to faster time-to-market and tighter cost control. Unfortunately, traditional project management approaches often involve complex coordination among multiple teams and repetitive setup tasks—leading to delays and increased risk of errors.
As AI and machine translation technologies evolve rapidly, language technology has become a critical enabler for companies expanding into global markets. However, many organizations still face significant challenges in real-world applications. Machine translation quality can be inconsistent, and manual proofreading
Nowadays, an increasing number of Chinese companies are actively expanding into overseas markets. In the process of going global, these enterprises have found that the environment they face is becoming increasingly complex and challenging due to factors such as geopolitics,
AI is revolutionizing drug regulation at every stage—from speeding reviews to improving safety monitoring and replacing animal testing. Here’s a clear and engaging breakdown, complete with real-world examples: 1. Faster, Smarter Drug Reviews Elsa: FDA’s Generative AI Assistant In early
According to a research report published by Spherical Insights & Consulting, the Global Automotive Industry Market Size was valued at USD 3,564.67 Billion in 2023 and is expected to reach USD 6,861.45 Billion by 2033, at a CAGR of 6.77%
Artificial Intelligence (AI) is revolutionizing life science sectors such as clinical trials and regulatory compliance. AI speeds up drug development through improved trial design, automation of compliance processes, data management, and streamlining. 1. AI‑Driven Clinical Trial Design and Execution The
Artificial Intelligence is transforming the pharmaceutical industry by solving old problems in drug development and clinical trial rules. This article shows how AI is changing the field. Introduction: Challenges in Pharma and the Rise of AI Developing a new drug
